Type 2 diabetes driving up ESRD (end-stage renal disease) in Canada
This article was originally published in Clinica
Executive Summary
Rising levels of type 2 diabetes is driving an increase in end-stage renal disease (ESRD) in Canada, according to a new report by the Canadian Institute for Health Information (CIHI). The incidence of ESRD in patients with diabetes has more than doubled over ten years, from 1,066 in 1995 to 2,139 in 2004, according to Treatment of End-Stage Organ Failure in Canada 1995-2004.
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.